VIDEO: BrainPath device reduced hematomas in most patients with intracerebral hemorrhages

BOSTON — The BrainPath device successfully surgically evacuated intracerebral hemorrhages in most patients enrolled in the ENRICH trial, Andrew Russman, DO, said in a Healio video during the American Academy of Neurology Annual Meeting.

According to Russman, medical director of the Comprehensive Stroke Center at the Cleveland Clinic and head of the Cleveland Clinic stroke program, patients with deep brain hemorrhages previously had few options.

The Early Minimally Invasive Removal of Intracerebral Hemorrhage (ENRICH) trial, the results of which were originally presented at the 2023 American Association of Neurological Surgeons Annual Meeting, enrolled about 300 patients with primarily lobar hemorrhages, he said.

The BrainPath device (Nico Corp.) is inserted via a craniotomy through the sulci in a parafascicular fashion to avoid hitting important structures as it enters the hematoma itself, Russman said.

“In the vast majority of patients, we were able to obtain a resulting hematoma that was less than 15 mL, which was the initial goal,” he said. “We are now able to extract the hematoma and see some incredible results for patients, reducing their disability and improving their clinical outcomes.”

Reference:

• Pradilla G, et al. Efficacy and safety of Early Minimally Invasive Removal of Intracerebral Hemorrhage (ENRICH): A multicenter randomized adaptive trial. Presented at: American Association of Neurological Surgeons Annual Meeting; April 21-24, 2023; Los Angeles.